Jack Lin

Stock Analyst at Morgan Stanley

(0.48)
# 3,998
Out of 4,355 analysts
24
Total ratings
27.8%
Success rate
-11.7%
Average return

Stocks Rated by Jack Lin

HUTCHMED (China)
May 28, 2026
Upgraded: Hold
Price Target: $14$14
Current: $11.45
Upside: +18.78%
InnoCare Pharma Limited
May 28, 2026
Upgraded: Buy
Price Target: $19.60$17.00
Current: $11.63
Upside: +46.17%
HUTCHMED (China) Limited
Mar 6, 2026
Maintained: Sell
Price Target: $21.40$21.45
Current: $18.32
Upside: +17.09%
Duality Biotherapeutics, Inc.
Nov 20, 2025
Maintained: Buy
Price Target: $493.00
Current: $225.60
Upside: +118.53%
Akeso, Inc.
Nov 9, 2025
Maintained: Buy
Price Target: $215.00
Current: $118.10
Upside: +82.05%
Zai Lab Limited
Nov 6, 2025
Maintained: Buy
Price Target: $37.50$37.44
Current: $13.91
Upside: +169.16%
RemeGen Co., Ltd.
Oct 30, 2025
Maintained: Hold
Price Target: $89.00
Current: $82.65
Upside: +7.68%
Innovent Biologics, Inc.
Sep 22, 2025
Maintained: Buy
Price Target: $123.00
Current: $83.35
Upside: +47.57%
Everest Medicines Limited
Sep 22, 2025
Maintained: Hold
Price Target: $55.00
Current: $30.14
Upside: +82.48%
Keymed Biosciences Inc.
Sep 22, 2025
Maintained: Buy
Price Target: $93.50
Current: $61.80
Upside: +51.29%
Maintained: Buy
Price Target: $50$48
Current: $17.69
Upside: +171.34%
Maintained: Buy
Price Target: $22.00
Current: $9.75
Upside: +125.64%